Increased expression of AIM2 has been reported in a number of inflammatory diseases, including inflammatory bowel disease and the skin conditions of psoriasis, atopic dermatitis and venous ulcers.102, 103, 104 In the skin, AIM2 upregulation is seen at sites of individuals with acute and chronic skin barrier disruption‐related inflammation, which can be as striking as more than a 300‐fold increase.103 AIM2 priming/upregulation upon skin barrier disruption serves as a first line of defense against invading pathogens. The gene discussed is AIM2; the disease is atopic eczema.